BioSpace News Archive

Results were shared in a poster presentation today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The data demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated patients with relapsed/refractory multiple myeloma (RRMM).

ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)

3D printer to create human tissue aboard International Space Station

The Supreme Cannabis Company, Inc., is pleased to announce the Company’s participation at select conferences in June.

COLVERA™ Blood Test Provides Improved Effectiveness Detecting Recurrence of Colorectal Cancer

$1.5 Million “Gateway Discovery Grants” to Fund Transformational Clinical Cancer Research

Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane®, approved by the U.S. Food and Drug Administration (USFDA)

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (the licence holder for SRA737) held an analyst and investor event today featuring distinguished oncologists Professor Johann de Bono and Dr Rebecca Kristeleit, to discuss clinical findings and possible next steps for SRA737, its oral, highly selective Chk1 inhibitor

This partnership will help Fast Pace to accelerate growth and further expand its reach to provide underserved rural populations with access to high-quality, affordable health care